ArticleACS bio & med chem Au2025
PLAIG: Protein-Ligand Binding Affinity Prediction Using a Novel Interaction-Based Graph Neural Network Framework.
Article in ACS bio & med chem Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- 3D Geometric Equivariant Graph Neural Networks with Contrastive Learning for Protein-Ligand Binding Affinity Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Predicting Enzyme pH Optima from Structure Using Equivariant Graph Neural Networks.Journal of chemical information and modeling · 2026Article
- MBind: A Web-Based Platform for Metalloprotein and Nonmetalloprotein Docking with Optional ML Docking Integration.Molecules (Basel, Switzerland) · 2026Article
- GRIPHIN: grids of pharmacophore interaction fields for affinity prediction.Journal of cheminformatics · 2026Article
- DualPG-DTA: A Large Language Model-Powered Graph Neural Network Framework for Enhanced Drug-Target Affinity Prediction and Discovery of Novel CDK9 Inhibitors Exhibiting In Vivo Anti-Leukemia Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Beyond Random Splits: Assessing the Generalization of Graph and Vector Models for WT-Structure-Only Drug Resistance Prediction under Protein-Disjoint Evaluation.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid prediction of protein-ligand binding affinity is important in the drug discovery process. The advent of machine learning methods has increased the speed of these predictions. Previous machine learning models based on structural, sequence, and interaction-based approaches have shown potential but often tend to memorize training data due to incomplete feature representations that lead to poor generalization on external complexes. To address this challenge, here, we developed PLAIG, a Graph Neural Network (GNN)-based machine learning framework for generalized binding affinity prediction. PLAIG represents binding complexes as graphs, integrating protein-ligand interactions and molecular topology to uniquely capture interaction and structural features. To reduce overfitting, we tested principal component analysis (PCA) and ensemble learning with a stacking regressor. During benchmarking, PLAIG achieved a PCC of 0.78 on 4852 complexes from the PDBbind v.2019 refined set and 0.82 on 285 complexes from the v.2016 core set, outperforming many existing models. External validation on the DUDE-Z data set demonstrated its ability to differentiate active ligands from decoys, achieving an average AUC of 0.69 and a maximum AUC of 0.89. To enrich de novo prediction capabilities for subsequent model versions, PLAIG was hybridized with sequence- and structure-based models. The hybrid models achieved an average PCC of 0.88 on well-known drug-target complexes, with the best reaching a PCC of 0.98. Future work will incorporate an explicit inclusion of a docking methodology into PLAIG's pipeline and assess its performance on de novo ligands. PLAIG is freely available at https://plaig-demo.streamlit.app/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.